Patterns of antiseizure medications prescribing in people with intellectual disability and epilepsy: A narrative review and analysis
British Journal of Clinical Pharmacology · 2023-07 · 89 (7) · 2028-2038
DOI: 10.1111/bcp.15748 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 03.05.2023. Verfasst von David Branford und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cornwall Intellectual Disability Equitable Research (CIDER), University of Plymouth Peninsula School of Medicine, Truro, UK. Hauptthemen laut MEDLINE: Intellectual Disability, Substance Abuse, Intravenous, Epilepsy, General Practice. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
People with intellectual disabilities (PwID) have a bidirectional relationship with epilepsy. Nearly 25% of PwID have seizures and 30% people with epilepsy are thought to have a significant intellectual impairment. Furthermore, 70% of PwID are thought to have treatment‐resistant epilepsy. In the United Kingdom, antiseizure medications (ASMs) are the second most widely prescribed psychotropic agent for PwID. However, it is unclear what the current evidence and patterns is on current prescribing of ASMs, including when and how a case is made to withdraw them. A narrative review along with an analysis of large‐scale NHS Digital published data (2015–2020) on several aspects of ASM prescribing by general practices for PwID was undertaken. The review results and data analysis are consolidated and presented as 11 themes to provide a comprehensive overview of the study topic. Recent studies estimate that one‐third and one‐fifth of PwID are prescribed ASMs. A history of epilepsy is seen as the primary prescribing reason; however, often it is a legacy, and the indication is no longer clear. The proportion receiving ASMs continues to rise with age. This pattern of use does not correlate well with seizure onset. There are limited data on de‐prescribing ASMs in PwID. The study population heterogenicity, associated polypharmacy, multimorbidity and higher sudden unexpected death in epilepsy risks are outlined. Suggestions are made from available evidence for improving prescribing practices for PwID and seizures, and key areas for further research in this complex clinical area are outlined.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cornwall Intellectual Disability Equitable Research (CIDER), University of Plymouth Peninsula School of Medicine, Truro, UK.
- Royal Free London NHS Foundation Trust, London, UK.
- Royal Cornwall Hospitals NHS Trust, Truro, UK.
- Cornwall Intellectual Disability Equitable Research (CIDER), Cornwall Partnership NHS Foundation Trust, Truro, UK.
ORCID-Profile: Rohit Shankar
Zitieren
APA
Branford, D., Sun, J. J., Burrows, L., & Shankar, R. (2023). Patterns of antiseizure medications prescribing in people with intellectual disability and epilepsy: A narrative review and analysis. British Journal of Clinical Pharmacology, 89(7), 2028-2038. https://doi.org/10.1111/bcp.15748
Vancouver
Branford D, Sun JJ, Burrows L, Shankar R. Patterns of antiseizure medications prescribing in people with intellectual disability and epilepsy: A narrative review and analysis. British Journal of Clinical Pharmacology. 2023;89(7):2028-2038. doi:10.1111/bcp.15748
BibTeX
@article{Branford2023,
author = {Branford, David and Sun, James J and Burrows, Lisa and Shankar, Rohit},
title = {Patterns of antiseizure medications prescribing in people with intellectual disability and epilepsy: A narrative review and analysis},
journal = {British Journal of Clinical Pharmacology},
year = {2023},
volume = {89},
number = {7},
pages = {2028--2038},
doi = {10.1111/bcp.15748}
}
EUVIMED